Observational Study of Best Supportive Care With or Without Surgery, Chemo or Radiotherapy in Pts With Carcinoma of Lung

INST 0701C: An Observational Outcomes Protocol of Standard Practice of Best Supportive Care With or Without Surgery, Chemotherapy or Radiotherapy in Patients With Carcinoma of the Lung

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00822016

Enrollment

Registered

2009-01-14

Start date

2007-07-31

Completion date

2011-03-31

Last updated

2012-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Best Supportive Care, Protocol of Standard Practice, Carcinoma of the Lung

Brief summary

The purpose of this study is to establish a listing (database) of patients diagnosed with lung cancer and treated with best supportive care and standard and investigational chemotherapy regimens, surgery, and radiation therapy at the UNM CRTC and other NMCCA sites. The information will be used to determine the results of various treatments for lung cancer subjects and to find where improvements can be made in safety, effectiveness, supportive care, treatment that eases tumors without curing them, treatments that cure tumors, prevention, and follow-up efforts. The database information will be compared to clinical trial data published in peer-reviewed journals and SEER outcome data. Patients will be acquired both before and after they are treated for lung cancer.

Detailed description

Same as above.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Those who are eligible for this treatment protocol will consist of: 1. Patients with histologically diagnosed lung cancer. 2. Patients receiving therapy should have an ECOG/Zubrod/SWOG performance status of \<3 at the time of the initiation of therapy. 3. All newly diagnosed patients referred to an NMCC Alliance site will be eligible, as will patients with recurrent disease that are now referred to an NMCCA for their next therapy (such as those who move from out of state, or are referred for protocol therapy), though efforts will be made to obtain records of prior therapy administered elsewhere).

Exclusion criteria

* Patients not falling under any of the above criteria are not eligible for the study. * Withdrawal of the informed consent at any point in the study excludes patient from the study.

Design outcomes

Primary

Measure	Time frame
To document the progression-free survival, rate of response, median duration of response, & median overall survivals, of subjects receiving best supportive care with or without standard surgery, chemotherapy and/or radiation therapy for lung cancer	3-6 months

Secondary

Measure	Time frame
To document the incidence and severity of toxicities, and reversibility of toxicities of subjects as a function of the treatments rendered.	3-6 months

Countries

United States

Outcome results